Most hair loss treatments target a single mechanism. Minoxidil improves blood flow. Finasteride blocks DHT. Neither addresses the Wnt/β-catenin pathway suppression that drives follicle miniaturization in androgenetic alopecia, and neither has meaningful anti-inflammatory effects on the scalp microenvironment. The peptide stack in this guide works differently: each compound addresses a distinct biological driver, and the three mechanisms are complementary rather than redundant.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide that increases VEGF production in dermal fibroblasts, stimulating microvascular angiogenesis and improving nutrient delivery to the dermal papilla. A 2026 review published in Biomedicines (Fan et al., HKUST) identified GHK-Cu as one of the few peptides with both mechanistic data and a published clinical study in AGA patients. PTD-DBM is a synthetic peptide that disrupts the CXXC5–Dishevelled interaction, removing a brake on the Wnt/β-catenin pathway — the master regulator of hair follicle cycling. In the foundational 2017 study (Lee et al., Journal of Investigative Dermatology), topical PTD-DBM outperformed minoxidil in a C3H mouse model. BPC-157 provides the scalp environment foundation: VEGFR2 upregulation, nitric oxide modulation, and suppression of the pro-inflammatory cytokines (TNF-α, IL-1β) that accelerate telogen effluvium and blunt the efficacy of the other two peptides.

Hair grows from follicles — self-contained mini-organs within the dermis. Each follicle cycles independently through three phases: anagen (active growth, lasting 3–10 years), catagen (regression, 2–3 weeks), and telogen (rest, 2–3 months). The length of the anagen phase determines hair length; the ratio of anagen to telogen follicles determines hair density. In healthy scalp, approximately 84% of follicles are in anagen at any given time.

The dermal papilla (DP) is the mesenchymal signaling hub at the base of each follicle. It receives blood supply from the subpapillary plexus and secretes growth factors (IGF-1, VEGF, FGF-7, HGF) that maintain the anagen phase. When blood supply is compromised, or when signaling pathways within the DP are suppressed, the follicle miniaturizes — producing progressively thinner, shorter hairs until it enters permanent telogen.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide first identified by Loren Pickart in 1973. It is found in human plasma, saliva, and urine, with plasma concentrations declining from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — a decline that correlates with reduced tissue repair capacity. The copper (Cu²⁺) ion is essential for its biological activity; the peptide acts as a copper chaperone, delivering Cu²⁺ to copper-dependent enzymes involved in collagen synthesis, antioxidant defense (SOD1), and angiogenesis.

PTD-DBM (Protein Transduction Domain — Dishevelled Binding Motif) is a synthetic peptide designed to disrupt a specific protein-protein interaction: the binding of CXXC5 to Dishevelled (Dvl). This interaction was identified as a key suppressor of the Wnt/β-catenin pathway in hair follicles by Lee et al. in 2017, in a landmark paper published in the Journal of Investigative Dermatology (Vol. 137, Issue 11, pp. 2260–2269; DOI: 10.1016/j.jid.2017.04.038).

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in gastric juice. It has an extensive preclinical literature on wound healing, angiogenesis, and anti-inflammatory effects across multiple tissue types. Its role in this hair loss stack is not as a direct hair growth stimulant — there are no published hair-specific RCTs — but as a scalp environment optimizer that creates the conditions in which GHK-Cu and PTD-DBM can work most effectively.

Use the quiz below to identify your hair loss type and receive a personalized protocol recommendation. If you've already completed the quiz above, scroll to your protocol directly.